EverHint Signal — Momentum Swing: Volatile High Beta — December 08, 2025

What This Signal Is (Quick)

Volatile High Beta is a momentum swing strategy aimed at traders who are comfortable living on the edge of the volatility curve. It focuses on stocks with elevated realized volatility (roughly 60–150% annualized), strong relative strength, and clean breakouts or consolidations near 52-week highs.

The signal for December 8, 2025 looks for:

• High-volatility, high-beta names
• Strong upside momentum and relative strength vs the market
• Breakouts or tight consolidations near 52-week highs
• Enough liquidity (solid dollar volume) to keep slippage under control

This is an experimental scanner, designed for research, back-testing, and idea generation—not a trade recommendation engine. The December 8 run surfaced 10 symbols that fit the Volatile High Beta profile.

How We Ranked Today (Reader Version)

For this Volatile High Beta report:

• Primary rank: a composite Score (0–100) that blends trend persistence, proximity to highs, volume behavior, and volatility profile.
• Secondary filters:
  • Volume thrust (today’s volume vs 20-day average)
  • Distance to 52-week high (all are close; one is slightly below)
  • Relative strength (rs_21) vs SPY to keep weak laggards out

On top of the raw breakout list, we overlay:

• Insider flows over the last 90 days (net open-market purchases vs sales)
• Earnings proximity (days until next earnings date and whether it’s BMO/AMC)
• Analyst estimates & coverage (for context on how closely institutions are watching these names)

Signals here are best treated as watchlist candidates for:

• Back-testing your own entry/exit rules
• Drilling into fundamentals and catalysts
• Comparing real-time price action against your own risk framework

Not financial advice—this is experimental research only.

⚡ Breakout Signals — Volatile High Beta (2025-12-08)

All names below triggered breakout-style momentum signals with elevated volatility and strong trend structures.

Quick field notes on the table

• Last ($) – Closing price on the signal date.
• Vol Thrust – Today’s volume vs 20-day average (e.g., 3.9x = almost 4× normal activity).
• % of 52W High – 100% = at or making new 52-week highs; DYN is the only name slightly below.
• Score (0–100) – Composite quality score; higher = cleaner, more “textbook” high-beta breakout.
• Market Cap – Rounded to B/M for quick size context.
• Insider Net (USD) – Net open-market insider flow over the last ~90 days (P buys – S sales). Negative values here indicate net selling, positive would be net buying, “–” means no material open-market activity.
• Days → Earnings – Calendar days until the next scheduled earnings report, with most names ~50–85 days out, i.e., earnings risk is present but not imminent.

Liquidity is solid across the board: even the smallest names are turning tens of millions of dollars per day in average dollar volume, with WBD and U up in the hundreds of millions to over a billion.

Recent Headlines & Catalysts (Selected)

These are context bullets, not endorsements. Always read the full filings and articles yourself.

• ARWR — Arrowhead Pharmaceuticals (biotech, vol leader)
  • Recently kicked off a Phase 1/2a study of ARO-MAPT in Alzheimer’s disease and other tauopathies, a high-visibility neurology program (Business Wire).
  • Earlier in the week, Arrowhead announced FDA Breakthrough Therapy designation for plozasiran in severe hypertriglyceridemia, reinforcing the pipeline’s perceived potential (Business Wire).
  • Institutional flows are active: fund-flow reports highlight position changes by large asset managers such as Fisher Asset Management (Defense World).
• PTGX — Protagonist Therapeutics
  • Conference data with partner Takeda showed longer-term control in polycythemia vera, supporting the durability narrative around the program (Business Wire).
  • New 13F-style disclosures mention Bosun Asset Management initiating a position, signaling fresh institutional interest (Defense World).
• APGE — Apogee Therapeutics
  • Management recently presented at Citi’s annual global healthcare conference, keeping the story in front of institutional audiences and sell-side analysts (Seeking Alpha).

Overall, the news backdrop is classic high-beta biotech + growth: clinical readouts, regulatory designations, and institutional positioning updates dominate the tape, which fits the “risk-on, volatility-friendly” profile of this scanner.

Field Notes — How This Basket Behaves

1. Volatility & beta profile

• Realized volatility (vol63) across the basket clusters around the 70–80% annualized zone, with some names stretching higher.
• This means a +/-5–7% daily move is not unusual; oversizing positions in this universe can quickly overwhelm risk limits.

2. Sector tilt

• Healthcare/biotech dominates (7 of 10 names), with a supporting cast of software (TDC, U) and media/streaming (WBD).
• This reflects a classic risk-on rotation into higher-beta growth themes, even on a day when the broad indices traded slightly red.

3. Volume thrust & liquidity

• Several names (NRIX, TERN, WBD, DYN, especially GPCR) show 3–9× normal volume, suggesting strong institutional participation rather than retail-only spikes.
• GPCR stands out with ~9.3× volume thrust at a fresh 52-week high—textbook high-beta breakout behavior that needs tight risk controls if traded.

4. Insider flows

• Where insiders are active in this scan, the net flows skew negative (sales), especially in APGE and U.
• While insider selling isn’t automatically bearish (taxes, diversification, expiring options), it’s a useful risk overlay for position sizing and conviction—especially in high-volatility biotech.
• Names with no meaningful recent open-market activity (e.g., TDC, GPCR, DYN) sit neutral on this dimension.

5. Earnings calendar

• Most names here are roughly 50–85 days from earnings, so traders have a multi-week window before the next binary event.
• For swing setups, that’s enough time to attempt 1–2 legs of a trade before you have to decide whether to hold into the print.

Vlad’s Take (EverHint)

Today’s market backdrop: S&P 500 −0.42%, Nasdaq −0.38%, Dow −0.48%, Russell 2000 −0.45%—a mild risk-off session with broad indices drifting lower rather than breaking. The VIX closed around 16.7, consistent with normal to slightly elevated volatility, not panic. Bitcoin (+0.77%) and Ethereum (+2.45%) pushed higher, while the 10-year Treasury yield ticked up to ~4.17% (+0.65%), adding a bit of pressure to long-duration growth stories.

Given that backdrop, this Volatile High Beta list feels like a tactical, not structural, opportunity set:

• I’d treat these as short- to medium-term swing candidates (1–4 weeks) with tiered entries rather than all-in positions.
• Position sizing should assume intraday swings of 5–10% are entirely normal in this universe; stops and scaling plans matter more than usual.
• The heavy biotech tilt plus modestly risk-off tape suggests selectivity over shotgun exposure—pick a couple of names you actually understand rather than trying to own the entire basket.

For example:

• ARWR, PTGX, GPCR screen well as “pure high-beta biotech momentum” with strong volume and pipeline news.
• WBD and U provide non-biotech beta with large, liquid footprints and strong volume thrust—useful if you want volatility but less exposure to binary clinical events.
• DYN, with sub-100% 52-week-high proximity and zero composite score, is more of a “late chaser”—interesting if momentum extends, but structurally weaker than the top of the list.

As always, the scanner is experimental. The value is in how you combine these outputs with your own process: multi-timeframe charts, options markets, and fundamental work.

Independent, data-driven signals.
No hype. No promotions. Absolutely Zero bias. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/.

✨ If this gave you insight, a quick like, share, or subscribe supports the continued work behind EverHint.